(Q37332696)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Antibody-mediated rejection: treatment alternatives and outcomes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

John Pirsch

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Millie Samaniego

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

published in

Transplantation Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

34-46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

National conference to assess antibody-mediated rejection in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Long-term results of ABO-incompatible living kidney transplantation: a single-center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Overcoming a positive crossmatch in living-donor kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

ABO-incompatible kidney transplantation using both A2 and non-A2 living donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Humoral theory of transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Significance of the positive crossmatch test in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Humoral Antibodies in Renal Allotransplantation in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Predicting kidney graft failure by HLA antibodies: a prospective trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

The Banff 97 working classification of renal allograft pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Successful results after 3 years' tacrolimus immunosuppression in ABO-incompatible kidney transplantation recipients in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Removal of preformed cytotoxic antibody using PROSORBA (Staph Protein-A-Silica) column without immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Treatment of antibody-mediated accelerated rejection using plasmapheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Current approaches to treatment of antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Rituximab as treatment for refractory kidney transplant rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Mycophenolate mofetil and its mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Leflunomide: mode of action in the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Rapamycin in transplantation: a review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Suppression of B cell activation by cyclosporin A, FK506 and rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Immunoglobulin G levels before and after lung transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

The effects of immunosuppressive agents on in vitro production of human immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Cyclosporin A and FK506 block the negative signaling mediated by surface IgM cross-linking in normal human mature B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Double filtration plasmapheresis in an ABO-incompatible renal transplantation: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

ABO-incompatibility in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Plasmapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

C4d-positive acute humoral renal allograft rejection: rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Antibody-directed therapy: past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Facing the enigma of immunomodulatory effects of intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Intravenous immunoglobulin-associated acute renal failure: case series and literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Acute renal failure associated with immunoglobulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Transplanting patients with a positive donor-specific crossmatch: a single center's perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Presensitization: the problem and its management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Successful rescue of refractory, severe antibody mediated rejection with splenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Transplant glomerulopathy: subclinical incidence and association with alloantibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Mechanism of action of rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Antibody-mediated rejection of a pancreas allograft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Treatment of humoral rejection with rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Rituximab therapy for acute humoral rejection after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Plasma cells: finding new light at the end of B cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Plasma cell differentiation and multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Rituximab for idiopathic membranous nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Immunosuppressive drugs for kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2008.08.004

10.1016/J.TRRE.2008.08.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027615%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference